The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this global event, Professor Yiding Chen from the Second Affiliated Hospital, Zhejiang University School of Medicine, presented results from the biomarker analysis of the DANCER study. Focusing on operable HER2-negative Luminal B breast cancer, the study explored biomarkers related to neoadjuvant dalpiciclib-based therapy, offering new perspectives for precision treatment. Oncology Frontier conducted an exclusive interview with Prof. Chen onsite at ASCO, where he detailed the background, findings, and clinical significance of the study—highlighting the crucial role biomarkers may play in predicting treatment response and opening new avenues for breast cancer care.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ESMO President-Elect Professor Giuseppe Curigliano of the European Institute of Oncology (IEO), Milan, Italy, presented findings from the patient-reported outcomes (PRO) analysis of the Phase III EMBER-3 trial. The data revealed changes in overall health status, quality of life, and physical function scores in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer treated with either imlunestrant alone or in combination with abemaciclib. Oncology Frontier conducted an exclusive interview with Professor Curigliano at the conference to discuss the clinical applicability of imlunestrant monotherapy and its combination with abemaciclib, as well as their impact on patient quality of life—offering new perspectives for clinical practice.

Antibody–drug conjugates (ADCs) targeting HER2 have already transformed the treatment landscape in advanced breast cancer and are now making their way into early-stage settings. At the 2025 ASCO Annual Meeting, Professor Junjie Li from Fudan University Shanghai Cancer Center presented results from a phase II clinical study investigating a novel HER2 bispecific ADC, TQB2102, in the neoadjuvant treatment of HER2-positive early breast cancer. The study delivered striking pathological complete response (pCR) results, suggesting strong potential for clinical impact. Below is an on-site interview with Professor Li, summarizing the key findings.